Biocon announced the launch of its Yesafili biosimilar, in competition now with Pavblu, for the aflibercept market. Dr. Reddy’s and its marketing partner Fresenius Kabi have received FDA approval for its rituximab biosimilar. Biocon Begins Marketing Its Aflibercept Biosimilar Yesafili Shreehas Tambe, Chief Executive Officer and Managing Director of Biocon Limited, said, “The commercial launch … Continue reading Biosimilar Bytes: Biocon’s Yesafili Launches and Dr. Reddy’s Rituximab Biosimilar Is Approved